Positive-CHMP-opinion-for-dabigatran-in-children

Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa ® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of ageNo approved therapy for the treatment and prevention of venous thromboembolic events in children until nowCurrent standard of care often associated with frequent monitoring of anticoagulation or daily injections1Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran ´s established and well-documented safety and efficacy profile in adults3
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news